Literature DB >> 26148263

Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases?

Raffaele Licinio1, Antonio Facciorusso2, Nicola Maurizio Castellaneta1, Alfredo Di Leo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26148263     DOI： 10.1038/ajg.2015.163

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  6 in total

1.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

2.  Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.

Authors:  H Rautiainen; M Färkkilä; M Neuvonen; T Sane; A-L Karvonen; H Nurmi; P Kärkkäinen; P J Neuvonen; J T Backman
Journal:  Aliment Pharmacol Ther       Date:  2006-12       Impact factor: 8.171

3.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Authors:  M Leuschner; K P Maier; J Schlichting; S Strahl; G Herrmann; H H Dahm; H Ackermann; J Happ; U Leuschner
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.

Authors:  Christophe Corpechot; Fabrice Carrat; Abbas Bahr; Yves Chrétien; Renée-Eugénie Poupon; Raoul Poupon
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

5.  A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.

Authors:  Kenichi Hosonuma; Ken Sato; Yuichi Yamazaki; Masatoshi Yanagisawa; Hiroaki Hashizume; Norio Horiguchi; Satoru Kakizaki; Motoyasu Kusano; Masanobu Yamada
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

6.  Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.

Authors:  G R Lichtenstein; B Bengtsson; L Hapten-White; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2008-11-13       Impact factor: 8.171
  6 in total
  2 in total

1.  Response to Licinio et al.

Authors:  Ken Sato; Kenichi Hosonuma; Motoyasu Kusano; Masanobu Yamada
Journal:  Am J Gastroenterol       Date:  2015-07       Impact factor: 10.864

Review 2.  Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.

Authors:  Francesca Saffioti; Kurinchi Selvan Gurusamy; Leonardo Henry Eusebi; Emmanuel Tsochatzis; Brian R Davidson; Douglas Thorburn
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.